| 1 |
33661190 | Targeting the IL-2 inducible kinase in melanoma; a phase 2 study of ibrutinib in systemic treatment-refractory distant metastatic cutaneous melanoma: preclinical rationale, biology, and clinical activity (NCI9922). | 2021 Apr 1 |
1 |
| 2 |
33932067 | Ibrutinib improves the efficacy of anti-CD19-CAR T-cell therapy in patients with refractory non-Hodgkin lymphoma. | 2021 Jul |
3 |
| 3 |
31899702 | Antitumor Potency of an Anti-CD19 Chimeric Antigen Receptor T-Cell Therapy, Lisocabtagene Maraleucel in Combination With Ibrutinib or Acalabrutinib. | 2020 May |
2 |
| 4 |
32563910 | Ibrutinib is not an effective drug in primografts of TCF3-PBX1. | 2020 Oct |
1 |
| 5 |
32581054 | CD3xCD19 DART molecule treatment induces non-apoptotic killing and is efficient against high-risk chemotherapy and venetoclax-resistant chronic lymphocytic leukemia cells. | 2020 Jun |
2 |
| 6 |
32861289 | Allogeneic Transplantation and Chimeric Antigen Receptor-Engineered T-Cell Therapy for Relapsed or Refractory Mantle Cell Lymphoma. | 2020 Oct |
1 |
| 7 |
32876369 | Synergistic effect of ibrutinib and CD19 CAR-T cells on Raji cells in vivo and in vitro. | 2020 Nov |
3 |
| 8 |
29743179 | A CD19/CD3 bispecific antibody for effective immunotherapy of chronic lymphocytic leukemia in the ibrutinib era. | 2018 Aug 2 |
4 |
| 9 |
27677739 | Kinase inhibitor ibrutinib to prevent cytokine-release syndrome after anti-CD19 chimeric antigen receptor T cells for B-cell neoplasms. | 2017 Jan |
1 |
| 10 |
28715249 | Durable Molecular Remissions in Chronic Lymphocytic Leukemia Treated With CD19-Specific Chimeric Antigen Receptor-Modified T Cells After Failure of Ibrutinib. | 2017 Sep 10 |
2 |
| 11 |
26813675 | Ibrutinib enhances chimeric antigen receptor T-cell engraftment and efficacy in leukemia. | 2016 Mar 3 |
1 |
| 12 |
23940282 | Egress of CD19(+)CD5(+) cells into peripheral blood following treatment with the Bruton tyrosine kinase inhibitor ibrutinib in mantle cell lymphoma patients. | 2013 Oct 3 |
1 |